Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$356.01 - $451.55 $830,927 - $1.05 Million
2,334 New
2,334 $1 Million
Q1 2022

May 16, 2022

SELL
$254.45 - $351.06 $394,397 - $544,143
-1,550 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$272.01 - $353.03 $421,615 - $547,196
1,550 New
1,550 $542,000
Q2 2021

Aug 16, 2021

SELL
$257.11 - $319.92 $203,116 - $252,736
-790 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$268.3 - $380.31 $211,957 - $300,444
790 New
790 $217,000
Q3 2020

Nov 13, 2020

SELL
$215.51 - $272.51 $194,390 - $245,804
-902 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$127.44 - $232.72 $114,950 - $209,913
902 New
902 $203,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.